Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Low-frequency bipolar versus high-frequency monopolar cortical and subcortical motor mapping in craniotomies for brain tumors.

Journal of neurosurgery·2026
Same author

Defining rapid early progression in glioblastoma-A volumetric approach.

Neuro-oncology advances·2026
Same author

Local Control and Survival Outcomes in Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma: The Mayo Clinic Experience.

Journal of pediatric hematology/oncology·2026
Same author

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

AJNR. American journal of neuroradiology·2026
Same author

Protocol for Neuro-Oncology Anywhere: Deploying Mayo Clinic's remote cognitive assessment battery and wearable device monitoring platform while assessing the impact of metformin on cognition and quality of life in patients with history of cranial radiation.

Contemporary clinical trials communications·2026
Same author

Cost-effectiveness of vorasidenib in treatment of isocitrate dehydrogenase-mutated low-grade glioma.

Cancer·2026

相关实验视频

Updated: Jun 16, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K

高度质瘤的免疫疗法

Nishika Karbhari1,2, Kelsey M Frechette3, Terry C Burns4

  • 1Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.

Cancers
|June 13, 2025
PubMed
概括

免疫疗法对高度质瘤 (HGGs) 包括质母细胞瘤 (GBM) 具有前景,但面临挑战. 尽管有前途的早期试验,但在HGG治疗的大规模研究中,还没有任何免疫疗法显著改善了结果.

关键词:
质母细胞瘤是什么质瘤 质瘤 是一种高度质瘤高度质瘤免疫学 免疫学 免疫学免疫疗法 免疫疗法

更多相关视频

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

相关实验视频

Last Updated: Jun 16, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.4K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

7.9K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

科学领域:

  • 神经瘤学神经瘤学
  • 免疫学 免疫学 免疫学
  • 临床试验 临床试验

背景情况:

  • 高度质瘤 (HGGs),特别是质母细胞瘤 (GBM),预后不佳,复发率高.
  • 免疫疗法为HGG治疗提供了一个有前途的途径,在其他癌症的成功基础上.
  • 显著的挑战,包括免疫抑制和瘤耐药性,限制了HGGs的免疫疗法的有效性.

研究的目的:

  • 在过去30年中,批判性地分析HGGs的免疫疗法策略.
  • 审查各种免疫疗法剂在HGG治疗中的临床前和临床试验.
  • 确定影响HGG免疫疗法的成功和失败的关键因素.

主要方法:

  • 在过去的30年里,在HGG中进行了PubMed搜索随机临床试验.
  • 专注于免疫检查点抑制剂,疫苗,瘤病毒,细胞因子和CAR T细胞.
  • 分析了临床前和临床试验数据,以评估免疫治疗的疗效.

主要成果:

  • 许多免疫疗法策略在HGGs的临床前和早期试验中显示出希望.
  • 较大,后期的临床试验一直未能显示出显著的,改变实践的益处.
  • 目前还没有任何免疫疗法被证明足够有效,以改变HGGs的临床实践.

结论:

  • 尽管具有强大的理论基础,但HGG免疫疗法尚未转化为显著的临床成功.
  • 未来的进展需要对过去的研究进行批判性评估,优化治疗开发和创新的组合疗法.
  • 持续的研究对于克服耐药机制和改善HGG患者免疫治疗结果至关重要.